All

Results: 6265-6276 of 76394

GomSpace reports a solid Q1 with 43% revenue growth and positive EBITDA

PR Newswire associated0

GAC Tops Hong Kong EV Sales in April, Advancing Its High-Quality Global Expansion Strategy

Photocure ASA: Results for the first quarter of 2026

Today Essity hosts its Capital Markets Day - Accelerating progress by sharpening focus and execution

BAE Systems – Trading update

Saba Capital Secures Major Liquidity Win for Herald Investment Trust Shareholders, Marking Sixth Successful Outcome of Seven Original UK Campaigns

PR Newswire associated0

Hyundai Mobis Develops Power Electric Systems Ready to All EV Models

PR Newswire associated0

Vention Introduces "One-Stop Shop" End-of-Line Packaging Automation, From Case Packing to Conveying and Palletizing at Interpack 2026, in Collaboration with Universal Robots

Apis Partners Announces Final Close of $1.23 Billion Fund III, Double its Predecessor

Sinch reports first quarter 2026 results - Americas and voice are drivers of another solid quarter

Navatar Brings AI-Powered Corporate Finance Advisory CRM to Salesforce for Investment Banks and Consulting Firms

Urethral stricture starts with narrowing of a short segment of urethral lumen. At early stages, it is managed by balloon dilatation or DVIU Urethrotomy. The open urethrotomy wound after dilatation or DVIU has to heal from the edges of the wound, which may take a longer time. In BEES-HAUS cell therapy, the cell transplant having proven successful engraftment, covering the urethrotomy wound, yielding clinical safety and efficacy may be considered to be included in the treatment guidelines after validation. Its simplified version, the BHES-HAUS (Buccal epithelium Hashed and Encapsulated in Scaffold—Hybrid Approach to Urethral Stricture) accomplished in one-go without need for cell culture in a lab, works on similar principles. After long term follow-up, BHES-HAUS minimally invasive approach may be worth combining with DVIU and balloon dilatation, as it may be able to provide longer duration of recurrence-free, good quality of life without need for intermittent self-catheterization.

Pioneering feat in regenerative medicine, the BEES-HAUS cell therapy: Paracrine effect and cell engraftment, together healing urethral stricture. Its simplified version, BHES-HAUS’ results to be presented in AUA 2026